Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...